基化导向的细胞质DNA降解控制了cGAS-STING介导的免疫反应对DNA损伤的反应
1Department of Urology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, P.R. China.
Cancer cell
|January 9, 2026
概括
通过cGAS-STING信号传递,DNA损伤会触发免疫反应,但癌症可以阻止这种反应. 我们发现USP7调节TREX1,控制DNA分解和免疫激活,为癌症免疫治疗提供了新的点.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 癌症中cGAS-STING通路的激活依赖于DNA损伤的细胞质DNA.
- 对于免疫治疗的cGAS-STING通路的临床应用已经显示出有限的成功.
- 了解DNA损伤和免疫治疗之间的联系至关重要.
研究的目的:
- 为了研究在细胞质DNA降解中的无化作用及其对cGAS-STING激活的影响.
- 阐明调节TREX1水平并影响免疫反应的机制.
- 确定增强放射性免疫治疗的潜在治疗点.
主要方法:
- 研究了E3泛素结合酶SPOP,二基酶USP7和细胞质DNA外核酶TREX1.1.之间的相互作用.
- 评估了SPOP突变和USP7过度表达对TREX1水平和DNA降解的影响.
- 分析了USP7表达,瘤透淋巴细胞和癌症患者疾病进展之间的相关性.
- 评估了USP7抑制剂在放射治疗后恢复免疫反应的疗效.
主要成果:
- 在DNA损伤后,对cGAS-STING的激活至关重要,因为TREX1的以ubiquitination为导向的降解.
- SPOP突变或USP7过度表达导致TREX1的增加,促进DNA降解和抑制免疫激活.
- 患者的USP7表达升高与瘤透性淋巴细胞的减少和化疗放射治疗的较差结果相关.
- USP7抑制剂降低TREX1水平,并增强对辐射的免疫反应.
结论:
- 这项研究揭示了一种新的机制,它将DNA损伤,TREX1调节和通过ubiquitination的免疫激活联系在一起.
- USP7在控制细胞质DNA水平和调节抗瘤免疫力方面发挥着关键作用.
- USP7抑制剂通过恢复cGAS-STING通路功能来提高放射性免疫疗法的疗效,这是一种有前途的策略.
相关概念视频
DNA Damage can Stall the Cell Cycle
10.0K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
10.0K
DNA Damage Can Stall the Cell Cycle
3.0K
In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
3.0K
Regulated Protein Degradation
8.7K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
8.7K
Anaphase Promoting Complex
3.3K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
3.3K
Covalently Linked Protein Regulators
8.6K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
8.6K
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K


